PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
PT2992017T
(pt)
*
|
2013-05-02 |
2021-01-29 |
Anaptysbio Inc |
Anticorpos dirigidos contra a morte programada 1 (pd-1)
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
CN114081946A
(zh)
|
2014-03-12 |
2022-02-25 |
耶达研究与开发有限公司 |
降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
ES2847311T3
(es)
|
2014-08-05 |
2021-08-02 |
MabQuest SA |
Reactivos inmunológicos que se unen a PD-1
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
EP3659621A1
(en)
|
2014-09-13 |
2020-06-03 |
Novartis AG |
Combination therapies for cancer
|
JP6827415B2
(ja)
|
2014-10-31 |
2021-02-10 |
メレオ バイオファーマ 5 インコーポレイテッド |
疾患の処置のための併用療法
|
TWI595006B
(zh)
*
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
MA41867A
(fr)
*
|
2015-04-01 |
2018-02-06 |
Anaptysbio Inc |
Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
|
MX2017015046A
(es)
|
2015-05-29 |
2018-05-17 |
Agenus Inc |
Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
TW201709929A
(zh)
|
2015-06-12 |
2017-03-16 |
宏觀基因股份有限公司 |
治療癌症的聯合療法
|
BR112018000768A2
(pt)
*
|
2015-07-13 |
2018-09-25 |
Cytomx Therapeutics Inc |
anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
|
CA2991628C
(en)
|
2015-07-16 |
2020-04-07 |
Bioxcel Therapeutics, Inc. |
A novel approach for treatment of cancer using immunomodulation
|
EA201890296A1
(ru)
*
|
2015-07-30 |
2018-08-31 |
Макродженикс, Инк. |
Pd-1-связывающие молекулы и способы их применения
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
EP3337826A1
(en)
|
2015-08-20 |
2018-06-27 |
Sutro Biopharma, Inc. |
Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
CN108368175B
(zh)
*
|
2015-09-29 |
2021-08-06 |
上海张江生物技术有限公司 |
Pd-1抗体及其用途
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
JP2018529719A
(ja)
*
|
2015-09-30 |
2018-10-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Alk陰性がんを処置するためのpd−1系結合アンタゴニストおよびalk阻害剤の組合せ
|
SG10202008325XA
(en)
|
2015-10-02 |
2020-09-29 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
RU2731202C2
(ru)
|
2015-10-08 |
2020-08-31 |
Макродженикс, Инк. |
Комбинированная терапия для лечения рака
|
MA43186B1
(fr)
*
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
GEP20217328B
(en)
|
2015-12-14 |
2021-12-10 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
BR112018012352A2
(pt)
|
2015-12-16 |
2018-12-11 |
Merck Sharp & Dohme Corp. |
anticorpos anti-lag3 e fragmentos de ligação ao antígeno
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
CN109069628A
(zh)
*
|
2016-01-14 |
2018-12-21 |
Bps生物科学有限公司 |
抗pd-1抗体及其用途
|
EP3964529A1
(en)
*
|
2016-01-22 |
2022-03-09 |
Mabquest SA |
Non-blocking pd1 specific antibodies
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
CU20180088A7
(es)
|
2016-02-17 |
2019-05-03 |
Novartis Ag |
Anticuerpos anti tgfbeta 2
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
DK3458478T3
(da)
*
|
2016-05-18 |
2021-03-22 |
Boehringer Ingelheim Int |
Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
|
CN106008714B
(zh)
*
|
2016-05-24 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-1人源化单克隆抗体及其应用
|
BR112018074463A2
(pt)
|
2016-05-27 |
2019-03-06 |
Agenus Inc. |
anticorpos anti-tim-3 e métodos de uso dos mesmos.
|
KR20190015377A
(ko)
|
2016-06-02 |
2019-02-13 |
브리스톨-마이어스 스큅 컴퍼니 |
불응성 호지킨 림프종에서의 니볼루맙을 사용한 pd-1 차단
|
PT3464368T
(pt)
|
2016-06-02 |
2023-08-17 |
Bristol Myers Squibb Co |
Utilização de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 no tratamento de linfoma
|
JP2019517512A
(ja)
|
2016-06-03 |
2019-06-24 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
結腸直腸癌を有する患者の処置における抗pd−1抗体の使用
|
EP3463454A1
(en)
|
2016-06-03 |
2019-04-10 |
Bristol-Myers Squibb Company |
Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
|
WO2017210624A1
(en)
|
2016-06-03 |
2017-12-07 |
Bristol-Myers Squibb Company |
Anti-pd-1 antibody for use in a method of treating a tumor
|
WO2017214182A1
(en)
*
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
JP2019517557A
(ja)
|
2016-06-10 |
2019-06-24 |
アイオー セラピューティクス インコーポレイテッド |
癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子
|
AU2017283480A1
(en)
|
2016-06-13 |
2019-01-24 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
KR102531889B1
(ko)
|
2016-06-20 |
2023-05-17 |
키맵 리미티드 |
항-pd-l1 및 il-2 사이토카인
|
RU2656181C1
(ru)
*
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
CN107814845B
(zh)
*
|
2016-09-14 |
2021-02-09 |
浙江特瑞思药业股份有限公司 |
新的抗pd-1纳米抗体及其应用
|
EP3515944A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
IL265800B2
(en)
|
2016-10-11 |
2023-10-01 |
Agenus Inc |
Anti-LAG-3 antibodies and methods of using them
|
CN110099925A
(zh)
|
2016-10-28 |
2019-08-06 |
百时美施贵宝公司 |
使用抗pd-1抗体治疗尿道上皮癌的方法
|
CN110062885A
(zh)
|
2016-11-01 |
2019-07-26 |
安奈普泰斯生物有限公司 |
针对t细胞免疫球蛋白和粘蛋白3(tim-3)的抗体
|
EP3666794A1
(en)
*
|
2016-11-01 |
2020-06-17 |
AnaptysBio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
MA46708B1
(fr)
|
2016-11-02 |
2021-10-29 |
Jounce Therapeutics Inc |
Anticorps anti-pd1 et leurs utilisations
|
CN110072890B
(zh)
|
2016-11-03 |
2022-11-29 |
百时美施贵宝公司 |
可活化的抗ctla-4抗体及其用途
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
AU2017368155B2
(en)
|
2016-11-30 |
2022-02-24 |
Oncomed Pharmaceuticals, Inc. |
Methods for treatment of cancer comprising TIGIT-binding agents
|
LT3551660T
(lt)
|
2016-12-07 |
2023-12-27 |
Agenus Inc. |
Antikūnai prieš ctla-4 ir jų naudojimo būdai
|
KR102603681B1
(ko)
|
2016-12-07 |
2023-11-17 |
아게누스 인코포레이티드 |
항체 및 이의 사용방법
|
JOP20190133A1
(ar)
|
2016-12-08 |
2019-06-02 |
Innovent Biologics Suzhou Co Ltd |
أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
|
CN106519034B
(zh)
|
2016-12-22 |
2020-09-18 |
鲁南制药集团股份有限公司 |
抗pd-1抗体及其用途
|
WO2018119474A2
(en)
*
|
2016-12-23 |
2018-06-28 |
Remd Biotherapeutics, Inc. |
Immunotherapy using antibodies that bind programmed death 1 (pd-1)
|
MA47208A
(fr)
*
|
2017-01-09 |
2019-11-13 |
Tesaro Inc |
Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
|
KR20190098263A
(ko)
|
2017-01-09 |
2019-08-21 |
테사로, 인코포레이티드 |
항tim-3 항체로 암을 치료하는 방법
|
MX2019008346A
(es)
|
2017-01-13 |
2019-09-09 |
Agenus Inc |
Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
|
EP3570870A1
(en)
|
2017-01-20 |
2019-11-27 |
Novartis AG |
Combination therapy for the treatment of cancer
|
CN110291109B
(zh)
|
2017-01-20 |
2023-01-31 |
大有华夏生物医药集团有限公司 |
人程序性死亡受体pd-1的单克隆抗体及其片段
|
EP3579874B1
(en)
|
2017-02-10 |
2021-07-21 |
Novartis AG |
1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
WO2018156740A1
(en)
|
2017-02-24 |
2018-08-30 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
AU2018229278A1
(en)
|
2017-02-28 |
2019-10-17 |
Sanofi |
Therapeutic RNA
|
EP3601355A1
(en)
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
CN117003887A
(zh)
|
2017-04-03 |
2023-11-07 |
豪夫迈·罗氏有限公司 |
抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
|
BR112019019821A2
(pt)
|
2017-04-05 |
2020-04-22 |
Hoffmann La Roche |
anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
CN106939049B
(zh)
*
|
2017-04-20 |
2019-10-01 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
|
EP3615572A1
(en)
|
2017-04-27 |
2020-03-04 |
Tesaro Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
CA3062061A1
(en)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
MA49144A
(fr)
|
2017-05-18 |
2020-03-25 |
Tesaro Inc |
Polythérapies pour le traitement du cancer
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
MX2019012038A
(es)
|
2017-05-30 |
2019-11-18 |
Bristol Myers Squibb Co |
Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
|
BR112019020610A2
(pt)
|
2017-05-30 |
2020-04-22 |
Bristol-Myers Squibb Company |
tratamento de tumores positivos para o lag-3
|
CA3065304A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
BR112019025035A2
(pt)
|
2017-06-01 |
2020-06-30 |
Compugen Ltd. |
método para tratar câncer
|
CN110678483B
(zh)
|
2017-06-01 |
2023-09-22 |
百时美施贵宝公司 |
用抗pd-1抗体治疗肿瘤的方法
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
TW201904993A
(zh)
|
2017-06-22 |
2019-02-01 |
瑞士商諾華公司 |
IL-1β 結合抗體之用途
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
PE20200717A1
(es)
|
2017-06-22 |
2020-07-21 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
KR20200029543A
(ko)
|
2017-07-13 |
2020-03-18 |
아이오 테라퓨틱스, 인크. |
암 면역요법을 위해 면역 조절제와 조합된 수용체 서브타입 및 기능 선택적 레티노이드 및 렉시노이드 화합물
|
SG11202000248UA
(en)
|
2017-07-14 |
2020-02-27 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗lag−3抗体の投薬量レジメンおよびその使用
|
ES2932354T3
(es)
|
2017-07-28 |
2023-01-18 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticáncer
|
SI3661954T1
(sl)
|
2017-08-03 |
2022-05-31 |
Amgen Inc. |
Muteini interlevkina-21 in postopki zdravljenja
|
JP7316263B2
(ja)
|
2017-08-31 |
2023-07-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
KR102651946B1
(ko)
|
2017-08-31 |
2024-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
WO2019046500A1
(en)
|
2017-08-31 |
2019-03-07 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
WO2019046591A1
(en)
|
2017-08-31 |
2019-03-07 |
Io Therapeutics, Inc. |
SELECTIVE RAR AGONISTS IN ASSOCIATION WITH IMMUNE MODULATORS IN ANTICANCER IMMUNOTHERAPY
|
CN111278854A
(zh)
|
2017-09-04 |
2020-06-12 |
艾吉纳斯公司 |
与混合谱系白血病(mll)特异性磷酸肽结合的t细胞受体和其使用方法
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
MA50657A
(fr)
|
2017-09-26 |
2020-08-05 |
Tesaro Inc |
Formulations de niraparib
|
MX2020003770A
(es)
*
|
2017-09-30 |
2020-07-29 |
Tesaro Inc |
Terapias de combinacion para tratar cancer.
|
US11801240B2
(en)
|
2017-10-06 |
2023-10-31 |
Tesaro, Inc. |
Combination therapies and uses thereof
|
KR20200061399A
(ko)
|
2017-10-10 |
2020-06-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
US20200239577A1
(en)
|
2017-10-15 |
2020-07-30 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
JP7254821B2
(ja)
|
2017-10-16 |
2023-04-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
US20210292415A1
(en)
|
2017-11-06 |
2021-09-23 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
TW201925782A
(zh)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
靶向bcma之嵌合抗原受體及其用途
|
WO2019117690A1
(ko)
*
|
2017-12-15 |
2019-06-20 |
경북대학교 산학협력단 |
Pd-l1에 결합하는 펩타이드 및 이의 용도
|
KR20200105862A
(ko)
|
2017-12-27 |
2020-09-09 |
테사로, 인코포레이티드 |
암을 치료하는 방법
|
EP3737408A1
(en)
|
2018-01-08 |
2020-11-18 |
Novartis AG |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
BR112020014121A2
(pt)
|
2018-01-12 |
2020-12-01 |
Amgen Inc. |
anticorpos anti-pd-1 e métodos de tratamento
|
KR20200109339A
(ko)
|
2018-01-16 |
2020-09-22 |
브리스톨-마이어스 스큅 컴퍼니 |
Tim3에 대한 항체를 사용하여 암을 치료하는 방법
|
WO2019144126A1
(en)
|
2018-01-22 |
2019-07-25 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
BR112020014574A2
(pt)
|
2018-01-22 |
2020-12-08 |
Bristol-Myers Squibb Company |
Composições e métodos para o tratamento do câncer
|
CN117402114A
(zh)
|
2018-01-26 |
2024-01-16 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
IL302626A
(en)
|
2018-01-26 |
2023-07-01 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
JP2021511357A
(ja)
|
2018-01-26 |
2021-05-06 |
エグゼリクシス, インコーポレイテッド |
キナーゼ依存的障害を処置するための化合物
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
CA3090479A1
(en)
|
2018-02-05 |
2019-08-08 |
Tesaro, Inc |
Pediatric niraparib formulations and pediatric treatment methods
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
WO2019161536A1
(en)
*
|
2018-02-23 |
2019-08-29 |
Eucure (Beijing) Biopharma Co. , Ltd |
Anti-pd-1 antibodies and uses thereof
|
JP7250808B2
(ja)
|
2018-03-08 |
2023-04-03 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
AU2019236865A1
(en)
|
2018-03-23 |
2020-10-01 |
Bristol-Myers Squibb Company |
Antibodies against MICA and/or MICB and uses thereof
|
JP2021519771A
(ja)
|
2018-03-30 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍を処置する方法
|
JP2021520201A
(ja)
|
2018-04-04 |
2021-08-19 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗cd27抗体およびその使用
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
EP3781202A4
(en)
*
|
2018-04-15 |
2022-01-05 |
Immvira Co., Limited |
PD-1 BINDING ANTIBODIES AND THEIR USES
|
BR112020021539A2
(pt)
|
2018-04-25 |
2021-01-19 |
Innate Tumor Immunity, Inc. |
Moduladores de nlrp3
|
EP3784688A2
(en)
|
2018-04-26 |
2021-03-03 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
TW202016136A
(zh)
|
2018-06-01 |
2020-05-01 |
瑞士商諾華公司 |
針對bcma之結合分子及其用途
|
MA52968A
(fr)
|
2018-06-23 |
2021-04-28 |
Hoffmann La Roche |
Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
AU2019301944B2
(en)
|
2018-07-10 |
2022-02-24 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases
|
KR20210034622A
(ko)
|
2018-07-18 |
2021-03-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
|
US20210261665A1
(en)
*
|
2018-07-19 |
2021-08-26 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-1 antibodies, dosages and uses thereof
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
EP3826660A1
(en)
|
2018-07-26 |
2021-06-02 |
Bristol-Myers Squibb Company |
Lag-3 combination therapy for the treatment of cancer
|
CN112888677A
(zh)
|
2018-08-16 |
2021-06-01 |
先天肿瘤免疫公司 |
被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法
|
CN112996567A
(zh)
|
2018-08-16 |
2021-06-18 |
先天肿瘤免疫公司 |
咪唑并[4,5-c]喹啉衍生的nlrp3-调节剂
|
CN113038989A
(zh)
|
2018-08-16 |
2021-06-25 |
先天肿瘤免疫公司 |
咪唑并[4,5-c]喹啉衍生的nlrp3调节剂
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
TW202024638A
(zh)
*
|
2018-09-04 |
2020-07-01 |
美商泰沙羅公司 |
治療癌症之方法
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
US20210347760A1
(en)
|
2018-10-03 |
2021-11-11 |
Tesaro, Inc. |
Niraparib Salts
|
US20210347758A1
(en)
|
2018-10-03 |
2021-11-11 |
Tesaro, Inc. |
Crystalline Forms of Niraparib Freebase
|
CN112839962A
(zh)
|
2018-10-09 |
2021-05-25 |
百时美施贵宝公司 |
用于治疗癌症的抗mertk抗体
|
CN112867803A
(zh)
|
2018-10-16 |
2021-05-28 |
诺华股份有限公司 |
单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
|
CN113286611A
(zh)
|
2018-10-19 |
2021-08-20 |
百时美施贵宝公司 |
用于黑色素瘤的组合疗法
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
AU2019380307A1
(en)
|
2018-11-16 |
2021-07-01 |
Bristol-Myers Squibb Company |
Anti-NKG2A antibodies and uses thereof
|
JP7469305B2
(ja)
*
|
2018-11-19 |
2024-04-16 |
バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド |
抗pd-1抗体およびその使用
|
EP3890749A4
(en)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
|
EP3891508A1
(en)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
EP3666905A1
(en)
|
2018-12-11 |
2020-06-17 |
Sanofi |
E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer
|
US20230029213A1
(en)
|
2018-12-13 |
2023-01-26 |
Exelixis, Inc. |
Crystalline Forms and Salt Forms of a Kinase Inhibitor
|
EP3897637A1
(en)
|
2018-12-20 |
2021-10-27 |
Novartis AG |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
CN113166762A
(zh)
|
2018-12-21 |
2021-07-23 |
欧恩科斯欧公司 |
新的偶联核酸分子及其用途
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
US20200369762A1
(en)
|
2018-12-21 |
2020-11-26 |
Novartis Ag |
Use of il-1beta binding antibodies
|
KR102371173B1
(ko)
|
2018-12-21 |
2022-03-04 |
오제 이뮈노테라프틱스 |
인간화된 항-인간-pd-1 항체
|
KR20210108422A
(ko)
|
2018-12-21 |
2021-09-02 |
노파르티스 아게 |
IL-1β 결합 항체의 용도
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
CN113228190A
(zh)
|
2018-12-23 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
基于预测的肿瘤突变负荷的肿瘤分类
|
EP3911417B1
(en)
|
2019-01-14 |
2022-10-26 |
Innate Tumor Immunity, Inc. |
Heterocyclic nlrp3 modulators , for use in the treatment of cancer
|
CN113286786A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
CN113710702A
(zh)
|
2019-01-14 |
2021-11-26 |
健泰科生物技术公司 |
用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
|
CN113301963A
(zh)
|
2019-01-14 |
2021-08-24 |
先天肿瘤免疫公司 |
用于治疗癌症的作为nlrp3调节剂的取代的喹唑啉类
|
JP2022517112A
(ja)
|
2019-01-14 |
2022-03-04 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Nlrp3モジュレーター
|
TW202043274A
(zh)
|
2019-01-21 |
2020-12-01 |
法商賽諾菲公司 |
用於晚期實性瘤癌症之治療性rna及抗pd1抗體
|
CA3126721A1
(en)
|
2019-01-25 |
2020-07-30 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
CA3129031A1
(en)
|
2019-02-12 |
2020-08-20 |
Novartis Ag |
Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
EA202192019A1
(ru)
|
2019-02-15 |
2021-11-02 |
Новартис Аг |
Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
|
CN113329792A
(zh)
|
2019-02-15 |
2021-08-31 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
KR20210146349A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
EP3946625A1
(en)
|
2019-03-28 |
2022-02-09 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
CA3134522A1
(en)
|
2019-04-19 |
2020-10-22 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
EP3966782A2
(en)
|
2019-05-06 |
2022-03-16 |
Tesaro, Inc. |
Methods for characterizing and treating a cancer type using cancer images
|
US20230295087A1
(en)
|
2019-05-13 |
2023-09-21 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
JP2022534967A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル-マイヤーズ スクイブ カンパニー |
多腫瘍遺伝子シグネチャーおよびその使用
|
JP2022534981A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよび組み合わせ治療
|
EP3976832A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
BR112021024300A2
(pt)
|
2019-06-03 |
2022-01-11 |
Exelixis Inc |
Formas de sais cristalinas de um inibidor de quinase
|
AR119069A1
(es)
|
2019-06-04 |
2021-11-24 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de quinasas
|
KR20220041079A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합
|
WO2020255011A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
WO2021003417A1
(en)
|
2019-07-03 |
2021-01-07 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
TWI809286B
(zh)
|
2019-07-05 |
2023-07-21 |
日商小野藥品工業股份有限公司 |
以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
EP4011918A4
(en)
|
2019-08-08 |
2023-08-23 |
ONO Pharmaceutical Co., Ltd. |
DUAL SPECIFIC PROTEIN
|
CR20220076A
(es)
|
2019-08-30 |
2022-06-24 |
Agenus Inc |
Anticuerpos anti-cd96 y sus métodos de uso
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
AU2020350795A1
(en)
|
2019-09-22 |
2022-03-31 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for LAG-3 antagonist therapy
|
CA3155341A1
(en)
|
2019-09-25 |
2021-04-01 |
Seagen Inc. |
Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
|
AU2020353079A1
(en)
|
2019-09-25 |
2022-04-14 |
Bristol-Myers Squibb Company |
Composite biomarker for cancer therapy
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
JP2022553306A
(ja)
|
2019-10-21 |
2022-12-22 |
ノバルティス アーゲー |
Tim-3阻害剤およびその使用
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
EP4055392A1
(en)
|
2019-11-05 |
2022-09-14 |
Bristol-Myers Squibb Company |
M-protein assays and uses thereof
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
BR112022008191A2
(pt)
|
2019-11-08 |
2022-07-12 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para melanoma
|
TW202130618A
(zh)
|
2019-11-13 |
2021-08-16 |
美商建南德克公司 |
治療性化合物及使用方法
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
US20230000864A1
(en)
|
2019-11-22 |
2023-01-05 |
Sumitomo Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
JP2023506187A
(ja)
|
2019-12-09 |
2023-02-15 |
シージェン インコーポレイテッド |
Liv1-adcおよびpd-1アンタゴニストとの併用療法
|
MX2022007464A
(es)
|
2019-12-18 |
2022-06-27 |
Tesaro Inc |
Composiciones biofarmaceuticas y metodos relacionados.
|
EP4077394A1
(en)
|
2019-12-19 |
2022-10-26 |
NGM Biopharmaceuticals, Inc. |
Ilt3-binding agents and methods of use thereof
|
MX2022006932A
(es)
|
2019-12-19 |
2022-07-11 |
Bristol Myers Squibb Co |
Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
US20230348458A1
(en)
|
2020-01-10 |
2023-11-02 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
CA3167413A1
(en)
|
2020-01-17 |
2021-07-22 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
US20230067202A1
(en)
|
2020-01-28 |
2023-03-02 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
AU2021213969A1
(en)
|
2020-01-30 |
2022-09-01 |
ONA Therapeutics S.L. |
Combination therapy for treatment of cancer and cancer metastasis
|
AU2021212197A1
(en)
|
2020-01-31 |
2022-08-04 |
BioNTech SE |
Methods of inducing neoepitope-specific T cells with a PD-1 axis binding antagonist and an RNA vaccine
|
CN115362167A
(zh)
|
2020-02-06 |
2022-11-18 |
百时美施贵宝公司 |
Il-10及其用途
|
US11577665B2
(en)
|
2020-02-27 |
2023-02-14 |
Cpk Interior Products |
Urethane and graphene interior trim panel
|
CA3173356A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor or a pd-1 inhibitor.
|
US20230235073A1
(en)
|
2020-03-06 |
2023-07-27 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
MX2022010912A
(es)
|
2020-03-06 |
2022-11-09 |
Celgene Quanticel Res Inc |
Combinacion de un inhibidor de desmetilasa-1 especifica de lisina (lsd-1) y nivolumab para usarse en el tratamiento de cancer de pulmon de celulas peque?as (sclc) o cancer de pulmon de celulas no peque?as escamosas (sqnsclc).
|
JP2023519254A
(ja)
|
2020-03-23 |
2023-05-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
がんを処置するための抗ccr8抗体
|
JP2023523193A
(ja)
|
2020-04-21 |
2023-06-02 |
ノバルティス アーゲー |
Csf-1rにより調節される疾患を治療するための投与レジメン
|
AU2021265801A1
(en)
|
2020-05-01 |
2022-11-17 |
Ngm Biopharmaceuticals, Inc. |
ILt-binding agents and methods of use thereof
|
BR112022022335A2
(pt)
|
2020-05-05 |
2023-01-10 |
Teon Therapeutics Inc |
Moduladores de receptor canabinoide tipo 2 (cb2) e usos dos mesmos
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
CA3187944A1
(en)
|
2020-06-22 |
2021-12-30 |
Ngm Biopharmaceuticals, Inc. |
Lair-1-binding agents and methods of use thereof
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
KR20230033647A
(ko)
|
2020-06-30 |
2023-03-08 |
멘두스 비.브이. |
난소암 백신에서 백혈병 유래 세포의 용도
|
JP2023532768A
(ja)
|
2020-07-07 |
2023-07-31 |
バイオエヌテック エスエー |
Hpv陽性癌の治療用rna
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
JP2023536264A
(ja)
|
2020-07-31 |
2023-08-24 |
エグゼリクシス, インコーポレイテッド |
がんの治療のための組み合わせ
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US20230314440A1
(en)
|
2020-08-21 |
2023-10-05 |
Exelixis, Inc. |
Method of treating cancer
|
WO2022047189A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
EP4204453A1
(en)
|
2020-08-31 |
2023-07-05 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
EP4208482A1
(en)
|
2020-09-02 |
2023-07-12 |
Pharmabcine Inc. |
Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
|
EP3970489A1
(en)
|
2020-09-18 |
2022-03-23 |
CpK Interior Products Inc. |
Graphene-based antiviral polymer
|
IL301533A
(en)
|
2020-09-24 |
2023-05-01 |
Merck Sharp ַ& Dohme Llc |
Stable compositions of programmed death receptor 1 (PD-1) antibodies and hyaluronidase variants and parts thereof and methods of using them
|
CN116406369A
(zh)
|
2020-10-05 |
2023-07-07 |
百时美施贵宝公司 |
用于浓缩蛋白质的方法
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
US20240101666A1
(en)
|
2020-10-23 |
2024-03-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
WO2022094567A1
(en)
|
2020-10-28 |
2022-05-05 |
Ikena Oncology, Inc. |
Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
AU2021374590A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
IL302396A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
WO2022119830A1
(en)
|
2020-12-02 |
2022-06-09 |
Genentech, Inc. |
Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
CA3201844A1
(en)
|
2020-12-17 |
2022-06-23 |
William W. Bachovchin |
Fap-activated radiotheranostics, and uses related thereto
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
AU2021416156A1
(en)
|
2020-12-28 |
2023-06-22 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
JP2024503265A
(ja)
|
2020-12-28 |
2024-01-25 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗体組成物およびその使用の方法
|
CN116723854A
(zh)
|
2021-01-22 |
2023-09-08 |
门德斯有限公司 |
肿瘤疫苗接种方法
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
WO2022187270A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
AU2022230384A1
(en)
|
2021-03-01 |
2023-09-07 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
CA3212351A1
(en)
|
2021-03-12 |
2022-09-15 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
IL307262A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20230170039A
(ko)
|
2021-04-13 |
2023-12-18 |
뉴베일런트, 아이엔씨. |
Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
|
JP2024516230A
(ja)
|
2021-04-30 |
2024-04-12 |
ジェネンテック, インコーポレイテッド |
がんのための治療及び診断方法並びに組成物
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
WO2022240741A1
(en)
|
2021-05-12 |
2022-11-17 |
Dana-Farber Cancer Institute, Inc. |
Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN117412767A
(zh)
|
2021-05-25 |
2024-01-16 |
雪绒花免疫公司 |
C-x-c基序趋化因子受体6(cxcr6)结合分子及其使用方法
|
CN113234160B
(zh)
*
|
2021-05-26 |
2022-05-27 |
广州爱思迈生物医药科技有限公司 |
一种抗pd-1抗体及其应用
|
WO2022256538A1
(en)
|
2021-06-03 |
2022-12-08 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
BR112023026966A2
(pt)
|
2021-07-02 |
2024-03-12 |
Hoffmann La Roche |
Métodos para tratar um indivíduo com melanoma, para alcançar uma resposta clínica, para tratar um indivíduo com linfoma não hodgkin, para tratar uma população de indivíduos com linfoma não hodgkin e para tratar um indivíduo com câncer colorretal metastático
|
WO2023285552A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
WO2023010094A2
(en)
|
2021-07-28 |
2023-02-02 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
CA3224180A1
(en)
|
2021-07-28 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
AU2022320051A1
(en)
|
2021-07-30 |
2024-01-25 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
TW202325306A
(zh)
|
2021-09-02 |
2023-07-01 |
美商天恩治療有限公司 |
改良免疫細胞之生長及功能的方法
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
WO2023057534A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
AU2022375806A1
(en)
|
2021-10-29 |
2023-12-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
TW202319073A
(zh)
|
2021-11-12 |
2023-05-16 |
瑞士商諾華公司 |
用於治療肺癌的組合療法
|
WO2023097211A1
(en)
|
2021-11-24 |
2023-06-01 |
The University Of Southern California |
Methods for enhancing immune checkpoint inhibitor therapy
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2023097195A1
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
WO2023111203A1
(en)
|
2021-12-16 |
2023-06-22 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
TW202340148A
(zh)
|
2021-12-22 |
2023-10-16 |
美商艾克塞里克斯公司 |
激酶抑制劑之結晶形式及鹽形式
|
WO2023122723A1
(en)
|
2021-12-23 |
2023-06-29 |
The Broad Institute, Inc. |
Panels and methods for diagnosing and treating lung cancer
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023173091A1
(en)
|
2022-03-11 |
2023-09-14 |
Ngm Biopharmaceuticals, Inc. |
Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
WO2023196964A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine learning identification, classification, and quantification of tertiary lymphoid structures
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
WO2023230554A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024015372A1
(en)
|
2022-07-14 |
2024-01-18 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
EP4310197A1
(en)
|
2022-07-21 |
2024-01-24 |
Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda |
Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
|
WO2024023740A1
(en)
|
2022-07-27 |
2024-02-01 |
Astrazeneca Ab |
Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024069009A1
(en)
|
2022-09-30 |
2024-04-04 |
Alentis Therapeutics Ag |
Treatment of drug-resistant hepatocellular carcinoma
|
WO2024077095A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
WO2024077166A1
(en)
|
2022-10-05 |
2024-04-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|